Ligand Pharmaceuticals Inc. said Friday that partner GlaxoSmithKline gained European regulatory approval to sell the blood disorder drug Revolade. In December, a European advisory committee recommended approving the drug. It was discovered by Ligand, is already approved in the U.S. as Promacta. Ligand's licensing partner GlaxoSmithKline handled the European ...

LONDON (Reuters) - Several drug firms have agreed on a landmark deal to supply up to 200 million doses a year of cut-price pneumococcal vaccines to developing nations, according to the global immunization alliance that is overseeing the deal. Leading manufacturers of such vaccines include GlaxoSmithKline and Pfizer. The agreement is the first under a new scheme called an Advance Market ...

Nabi Pharmaceuticals said Monday it closed an option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. The deal is potentially worth more than $500 million, including a $40 million upfront payment to Nabi and future milestone and royalty payments. Nabi shareholders voted in favor of the deal ...

AMSTERDAM (Reuters) - The Dutch government wants to sell 21 million unused H1N1 flu vaccine doses back to their manufacturers after they proved unnecessary and no other country wanted to buy them, the Health Ministry said on Saturday. A spokeswoman for the ministry said it had approached manufacturers GlaxoSmithKline and Novartis about buying back the doses. She added that it was ...